A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer

Inclusion Criteria:

* Age ≥18 years, Male;
* diagnosed as prostate cancer by histopathology or cytology;
* Confirmed as castration-resistant prostate cancer: 1 interval 1 week, 3 consecutive PSA minimum values increased by \>50%; 2 serum testosterones \<50ng/dl or \<1.7nmol/L \[Guide of the Chinese Urological Association (2015) The diagnostic criteria of CRPC\];
* There are no other concurrent anti-cancer treatments (including local radiotherapy, systemic chemotherapy, and molecular targeted therapy) or previous treatment history;
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
* The estimated survival period is more than 3 months;
* having at least one measurable lesion according to the RECIST 1.1 tumor evaluation criteria;
* No obvious signs of hematological disease, ANC≥1.5×109/L, platelet count≥100×109/L, Hb≥90g/L, WBC≥3.0×109/L, and no bleeding tendency before enrollment;
* Liver function test: total bilirubin (TBIL) ≤1.5 times the upper limit of normal value, alanine aminotransferase (ALT), aspartate aminotransferase (AST) are ≤2.5 times the upper limit of normal value, if due to liver metastasis, the above indicators ≤5 times the upper limit of normal value; renal function test: serum creatinine (Cr) ≤ 1.5mg/dl, or calculated creatinine clearance rate ≥50ml/min;
* Understand the circumstances of this study, patients and/or legal representatives voluntarily agree to participate in the trial and sign informed consent.

Exclusion Criteria:

* • Have a birth plan during the clinical trial;

  * Patients with brain metastases;
  * Severe cardiovascular diseases such as cerebrovascular accidents occurring within 6 months, myocardial infarction, hypertension that cannot be controlled after drug intervention, unstable angina pectoris, heart failure (NYHA 2-4), and arrhythmia requiring drugs Intervention;
  * Dementia, mental state changes or any mental illness that may interfere with understanding or making informed consent or completing a questionnaire;
  * Subjects with ≥1 peripheral neuropathy according to CTCAE V version 4.03;
  * Allergy or hypersensitivity history of the drug or drug ingredient used in this test;
  * Excluding other malignant tumors, cured basal cell carcinoma of the skin or squamous cell carcinoma of the skin or any other part of the carcinoma in situ;
  * Have received any other test drug treatment or participated in another interventional clinical trial within 30 days of the screening period;
  * The investigator believes that it is not suitable for inclusion.